Anthrax
Bayer Commits To Supply 200 Million Cipro Tablets Over Next Three Months
Published in Medical Letter on the CDC and FDA, December 9th, 2001
Bayer Corp. has committed to increase manufacturing to supply 200 million Cipro tablets over the next three months, 15 million tablets a week. Cipro (ciprofloxacin) is an effective antibiotic for 14 indications, including anthrax. The company plans to run its Cipro production facilities on a 24-hour, seven-day-per-week schedule and reopen one of its manufacturing plants. The company said it is prepared to send out shipments daily, including weekends.
"We have fulfilled every order to date from the U.S. government with the requested delivery schedule, and we are prepared to work with the government to fulfill future orders," said Karen A. Dawes, senior vice president...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Malaria
Levels Of Antibodies At Liver Stage May Predict Resistance To Disease - Vaccinations
Immunization Rates Remain High Among Vulnerable Children - Bioterrorism
Inspectors Find Security Lapses At CDC Lab In Colorado - Ethics
Hopkins Sanctions Scientist For Cancer Drug Trial - Hepatitis HEV
Hepatitis E Recovered From Rats In Los Angeles - Malaria
Researchers Identify Gene In Burkina Faso Population That Prevents Disease - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
